Comparative Pharmacology
Head-to-head clinical analysis: MEASURIN versus NEOPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEASURIN versus NEOPROFEN.
MEASURIN vs NEOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Measurin is an aspirin preparation that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin and thromboxane synthesis. This results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
IV: 10 mg/kg over 15 minutes, followed by 5 mg/kg at 24, 48, and 72 hours after the first dose.
None Documented
None Documented
Plasma elimination half-life is 2-3 hours at low doses (antiplatelet) and increases to 15-30 hours at anti-inflammatory doses due to saturation of hepatic metabolism; clinical context: higher doses require longer dosing intervals to avoid accumulation.
Terminal elimination half-life is approximately 2.5 to 4 hours in adults. In preterm neonates (target population for Neoprofen), half-life is prolonged due to immature renal function: mean 30.5 hours (range 20–50 hours) after first dose, decreasing to ~15 hours after third dose. Clinical relevance: requires careful dosing intervals in neonates to avoid accumulation.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid) accounts for >90% of elimination; minor biliary/fecal excretion (<5%) occurs.
Ibuprofen is primarily excreted renally as metabolites (approximately 90% of the dose), with less than 1% excreted unchanged. A small fraction (≤10%) is eliminated via bile/feces. For Neoprofen (ibuprofen lysine specifically used for patent ductus arteriosus), renal excretion accounts for >90% of elimination, predominantly as glucuronide conjugates and hydroxylated metabolites.
Category C
Category C
NSAID
NSAID